Zedira Raises Additional Funding

Published On May 23, 2010 |
Zedira GmbH, a Darmstadt, Germany-based biotech company which focuses on celiac disease and consequently also on the transglutaminases family of enzymes, has recieved a minority investment from R-Biopharm AG.
High-Tech Gründerfonds, which in September 2007 led the Series A financing round of the company, has further invested in the company. Zedira also received funding by the Federal Ministry of Education and Research.
With this strategic investment, R-Biopharm AG has secured exclusive access to the celiac disease specialist’s products.

Zedira develops, produces and markets products for research and development as well as for diagnostics. Based on its patented family of low-molecular transglutaminase blockers, the company is establishing an active ingredient pipeline covering the primary indication of celiac disease. Zedira is also working on new approaches to thrombosis prophylaxis.
Founders of the company are Dr. Martin Hils and Dr. Ralf Pasternack. 
Commenting on the reason behind the investment, Dr Ralf Dreher, R-Biopharm AG’s managing director, was quoted as saying: “Zedira has positioned itself as a producer of high-quality diagnostic antigens, paired with comprehensive scientific understanding of celiac disease.
“Its work at the interface between diagnostics and therapy generates products that are of interest to R-Biopharm because of their unique selling propositions”.
FinSMEs
23/05/2010

Like this Article? Share it!

One Response to Zedira Raises Additional Funding

  1. FinSMEs says:

    Zedira GmbH has just licensed exclusive rights to develop and market ZED-101 in Europe to Dr. Falk Pharma GmbH, Germany.
    ZED-101 is a new chemical entity blocking specifically tissue transglutaminase. Tissue transglutaminase is the key player in pathogenesis of celiac disease.

    Under the terms of the agreement, Dr. Falk Pharma GmbH takes over preclinical and clinical development as well as marketing of the drug. Zedira receives an upfront payment and may receive further milestone payments as well as royalties.

    FinSMEs

    25/11/2011

Leave a Reply